Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Implementation & Service Delivery

Ketamine for Implementation & Service Delivery

4 papers and 9 clinical trials exploring ketamine as a treatment for implementation & service delivery.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
IndicationApproximately 264 million people worldwide suffer from depression, while substance use disorders affect around 35 million globally.

Implementation & Service Delivery

This report explores the implementation and service delivery of psychedelic therapies, focusing on compounds such as psilocybin, MDMA, and LSD in various therapeutic contexts. Recent legislative efforts and clinical trials indicate a growing acknowledgement of the therapeutic potential of psychedelics, particularly in addressing mental health conditions and substance use disorders.

Full Implementation & Service Delivery profile

Academic Research

4 papers
Paywallmeta

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression

The paper uses ketamine as a case study to show that market and regulatory failures allowed a costly patented intranasal s‑ketamine (Spravato®) to be commercialised while inexpensive generic racemic ketamine—apparently at least as effective—remained under‑evaluated and largely inaccessible. The authors recommend systemic reforms, including commercial incentives, public and public–private funding, reduced regulatory barriers and coordinated international funding, to ensure affordable off‑patent treatments become accessible.

Published
October 13, 2023
Journal
Australian and new-zealand Journal of Psychiatry
Authors
Rodgers, A., Bahceci, D., Davey, C. G., Chatterton, M. L., Glozier, N., Hopwood, M., Loo, C.
Paywallindividual

Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program

This pilot program (n=8, +2 Elders) explored the effectiveness and safety of group-based therapy augmented by three sessions of ketamine at a psychedelic dose for Indigenous participants in partnership with Roots to Thrive and the Snuneymuxw First Nation. Thematic analysis of qualitative interviews and feedback revealed participant motivations, perceived barriers, program benefits, and psychedelic experiences. Participants emphasized the importance of Indigenous team members, incorporating traditional healing approaches, and fostering authentic relationships between participants and facilitators, highlighting both challenges and significant program benefits. The article underscores the need for reconciliation efforts within and beyond psychedelic therapies.

Published
September 18, 2023
Journal
Journal of Psychoactive Drugs
Authors
Manson, E., Ryding, E., Taylor, W., Peekeekoot, G., Gloeckler, S. G., Allard, P., Johnny, C., Greenway, K. T., Dames, S.
Paywallindividual

Two Models of Legalization of Psychedelic Substances: Reasons for Concern

This opinion paper (2021) raises concerns over the two concurrent models of legalizing the possession, personal use, and noncommercial sharing of psychedelics in California and clinical use in Oregon. In light of cautionary precedents involving the commercialisation of ketamine and cannabis, their chief concern is that non-evidence-based marketing strategies founded on one-sided enthusiasm for the benefits of psychedelics may supplant evidence-based practices, thereby putting vulnerable populations at risk of their potential side effects that have not been studied outside of the clinical population.

Published
August 3, 2021
Journal
JAMA
Authors
Smith, W. R., Appelbaum, P. S.
Open Accessindividual

Low-dose ketamine for treatment resistant depression in an academic clinical practice setting

This open-label retrospective study (n=41) evaluated the efficacy and safety of intravenous ketamine (35mg/70kg) infusion in a sample of patients who had treatment-resistant depression (TRD) and were being treated in a ‘naturalistic’ clinical context. Low-dose ketamine was efficacious and generally well-tolerated in the sample population, as participants reported improvements in depressive symptoms with a 53.7% response rate 24 hours post-infusion.

Published
October 15, 2017
Journal
Journal of Affective Disorders
Authors
Feifel, D., Malcolm, B., Boggie, D., Lee, K.

Clinical Trials

9 trials
Active not recruitingPhase II

Ketamine Therapy for Methamphetamine Use Disorder & HIV (KetaMet)

Single-arm pilot feasibility trial (n=12) of intramuscular ketamine (0.50–0.75 mg/kg IM, 3 doses ~once weekly) combined with manualised psychotherapy (7 sessions) for publicly insured patients with moderate-to-severe methamphetamine use disorder who have or are at-risk for HIV.

Started
January 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06538285
RecruitingPhase IV

Ketamine-assisted psychotherapy for methamphetamine use disorder

Open-label, non-randomised Phase IV pilot (n=20) evaluating safety and feasibility of manualised 4-session CBT with three adjunctive subcutaneous ketamine doses (weekly, weeks 2–4) for adults with methamphetamine use disorder.

Started
September 2, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12624000895583
RecruitingPhase IV

Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression (TREK)

This interventional trial, led by The George Institute, aims to compare the effectiveness of two formulations of ketamine (esketamine (Spravato®) and racemic ketamine), in treating treatment-resistant depression (TRD).

Started
April 1, 2024
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
NCT06278779
Enrolling by invitationPhase NA

Long Term Follow Up KET-PD

This observational cohort study (n=40), conducted by Yale University, aims to explore the long-term effects of ketamine for treating depression in Parkinson's disease (PD) and assess the impact of Cognitive Behaviour Therapy (CBT) on maintaining the effects of ketamine.

Started
October 18, 2023
Type
observational
Randomized
No
Registry ID
NCT06164756
Unknown statusPhase I

Ketamine Therapy Experiential Education Study

This interventional trial (n=500) designated as Ketamine Therapy Experiential Education Study (KTEES1), sponsored by Integrative Psychiatry Institute, investigates the effects of low-dose ketamine, administered intramuscularly to clinicians within a psychedelic-assisted therapy (PAT) training programme.

Started
September 1, 2022
Type
observational
Blinding
none
Randomized
No
Registry ID
NCT05468047
CompletedPhase I

Inpatient Single Dose Interventions for Alcohol Use Disorder

This interventional, randomised pilot feasibility study (n=44, age 18-65) aims to assess the potential of single-dose interventions (including ketamine) in reducing re-admissions for hospitalised patients with severe alcohol use disorder (AUD).

Started
January 19, 2022
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT04562779

Explore further

Search all Ketamine papers Search all Implementation & Service Delivery trials Full Ketamine profile Full Implementation & Service Delivery profile